Drugs / TSR-033
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03250832 | Aug 2017 → Jun 2022 | neoplasm | Tesaro, Inc. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02817633 Background | Jul 2016 → Mar 2027 expected | neoplasm | Tesaro, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TSR-033 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03250832 ↗ |
| Known as | encelimab | “CITRINO, a two-part, Phase 1 dose-escalation study, evaluated encelimab (TSR-033; novel anti-LAG-3) monotherapy and in combination in patients with advanced/metastatic solid tumours.” PMID 40016550 ↗ Feb 2025 |
| Modality | Monoclonal antibody | “TSR-033 is a humanized monoclonal antibody immunoglobulin (Ig) G4.” NCT03250832 ↗ |